{"name":"Umecrine Cognition AB","slug":"umecrine-cognition-ab","ticker":"","exchange":"","domain":"umecrinecognitionab.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"golexanolone","genericName":"golexanolone","slug":"golexanolone","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"golexanolone","genericName":"golexanolone","slug":"golexanolone","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOaFJvZ2ZEbkhJQkdSUndLcmZEdjd5NDQ3ZXAzaGRHbXNQa0NWcVQ4UVpZbF9MaF84eHVDVHZKUTQwN1VMZEc4R2oyV2lzR000NlBYcS1GUElHcWxHa09UUEJLd1k3NG45ZkZteVByd3I5QXdxSnpoRUFramNUak5oU1Nscm91R0kyUExYckRvUmhGSDFBU3dQakdmQl9CTGRnZ0lhTU41S1lnYWJaWHA3X09uQnlPem1IRWhLbg?oc=5","date":"2026-04-07","type":"pipeline","source":"TradingView","summary":"Notice of Annual General Meeting in KDventures AB (publ) - TradingView","headline":"Notice of Annual General Meeting in KDventures AB (publ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9MWkt6RHdabWN3em9RRnY1bHpiVDg4RllsbVZhXzBfZkE2VkpxWlpBQWJBSDdQTGl6aUE3UFBydmY1RGh5Q3doblItUFJoWk9aQ0hFNDh5UTlvWHItejRVM1hGaml0cVplaHlmVFVfMUVTQUtfM0xaTTVn?oc=5","date":"2024-10-30","type":"pipeline","source":"Straits Research","summary":"Overt Hepatic Encephalopathy Market Size, Global Trends, Top Share, Forecast to 2033 - Straits Research","headline":"Overt Hepatic Encephalopathy Market Size, Global Trends, Top Share, Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOT0xTNmFlMUZOelYwUmVnMUJIaWFlRGRCYjQzeVRYWGtRbmsxYnU0OUNtbDZlSVRPd2UxN2hseEE4QU1NVzRoQy10SlFBWmNfYzNzQkRVbFJQbGk5aXltYmEyWWExelRIdmNRc0FUZTlvaTRFcEdLWGNQZE1DcW5kTTNSNnh6VTdxcGR1bmhSSGd4RHhmcDR1RXN6emVDQm9ZTktRZkV2dm4xNnd3?oc=5","date":"2019-05-06","type":"pipeline","source":"Issuewire","summary":"Hepatic Encephalopathy Market to Surpass US$ 4,151.3 Million by 2026 - Issuewire","headline":"Hepatic Encephalopathy Market to Surpass US$ 4,151.3 Million by 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPalc3MWJhV0g1V01XUWJZZ04yWTVLbDAzbDdoVlppOWhLT2JHZjVEdWd1bVV3R2xQZGdTMXd1c3Q4aEhzbGEyZmRGcG1uMlBEa3pfRUJjejFKLTVpWGwzZm9MTEpXa2dLMVkzMHR2REtjaVk2OUMwZEhxWTFsYTJpWlBZLW1vU01LYUxoNHR3?oc=5","date":"2017-03-27","type":"trial","source":"European Pharmaceutical Review","summary":"Karolinska Development company enrols first patient Phase Ib/IIa hepatic encephalopathy trial - European Pharmaceutical Review","headline":"Karolinska Development company enrols first patient Phase Ib/IIa hepatic encephalopathy trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}